Effect of Rituximab Use on Hepatitis B Reactivation in Individuals with Resolved Hepatitis B Infection and Rheumatic Disease: A Single Center Study

Basit Öğe Kaydı
dc.contributor.authorErdoğan, Esra
dc.contributor.authorErdoğan, Mehmet Ali
dc.contributor.authorYolbaş, Servet
dc.contributor.authorKeser, Muhammed Furkan
dc.contributor.authorAydin, Saliha
dc.date.accessioned2026-04-04T13:19:06Z
dc.date.available2026-04-04T13:19:06Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.description.abstractHepatitis B infection is a global disease with significant morbidity and mortality rates. This study aims to evaluate the frequency of HBV reactivation in patients with resolved HBV infection using rituximab for the treatment of various rheumatological diseases. Patients receiving rituximab therapy for the treatment of rheumatic diseases were retrospectively screened for serological HBV infection markers (HBV DNA, HBsAg, anti-HBc IgG and anti-HBs). Twenty-five patients with resolved HBV infection who were HBV DNA-negative, HBsAg-negative and anti-HBc IgG-positive were included in the study. Twenty-two patients were female (88%) and three were male (12%). The average age of the patients was 62.56±9.786 years. Out of 25 patients, 22 had rheumatoid disease, two had Sjögren's syndrome, and one patient had systemic lupus erythematosus. While anti-HBs was positive in 15 patients, anti-HBs was negative in 10 patients. The mean HBsAg titer of the patients before treatment was 0.27±0.102, while the anti-HBs titer was 211.00±317.380 IU/L. Hepatitis B reactivation was not observed in any of the patients included in the study. Hence, the data suggest that patients with rheumatological diseases have a low risk of reactivation of HBV infection under rituximab treatment. However, prospective, multicenter studies involving more patients are needed to reach definitive conclusions. © 2024, Inonu University. All rights reserved.
dc.identifier.doi10.33715/inonusaglik.1467613
dc.identifier.endpage701
dc.identifier.issn2147-7892
dc.identifier.issue2
dc.identifier.scopus2-s2.0-105001437831
dc.identifier.scopusqualityQ4
dc.identifier.startpage692
dc.identifier.trdizinid1278973
dc.identifier.urihttps://doi.org/10.33715/inonusaglik.1467613
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1278973
dc.identifier.urihttps://hdl.handle.net/11616/108159
dc.identifier.volume12
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isotr
dc.publisherInonu University
dc.relation.ispartofJournal of Inonu University Vocational School of Health Services
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250329
dc.subjectHBV reactivation
dc.subjectHepatitis B virus
dc.subjectRheumatological diseases
dc.subjectRituximab
dc.titleEffect of Rituximab Use on Hepatitis B Reactivation in Individuals with Resolved Hepatitis B Infection and Rheumatic Disease: A Single Center Study
dc.title.alternativeÇÖZÜLMÜŞ HEPATİT B ENFEKSİYONLU VE ROMATİZMAL HASTALIĞI OLAN BİREYLERDE RİTUKSİMAB KULLANIMININ HEPATİT B REAKTİVASYONU ÜZERİNE ETKİSİ: TEK MERKEZLİ BİR ÇALIŞMA]
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu